Novogen Limited, an Australian and U.S. biotechnology company focused on new
treatments for cancer, is making headlines recently as its pre-clinical
family of drugs is demonstrating the ability to attack and kill cancer
stem cells in vitro, thus allowing for the possibility of a much more
effective and directed chemotherapy that isn't any more toxic to
non-cancer cells in the body. Cancer stem cells
are a key driver of the disease's spread even after treatment as they
can self-renew and regenerate a tumor after it has been treated by
existing chemotherapy drugs. NVGN believes that its drugs will be able
to demonstrate successful cancer remission once it conducts clinical
trials, thus making its chemotherapies the ideal compliment or
replacement to treatments for all types of cancers.
Novogen has four novel cancer treatments in its pipeline. The first for
ovarian cancer is backed by Yale studies; Phase 1 is projected to start
Q3 of 2015.
No comments:
Post a Comment